REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF TWO PHASE 3 STUDIES OF SECUKINUMAB

被引：0
|
作者：
Kvien, T. K. [1 ]
Conaghan, P. G. [2 ]
Deodhar, A. [3 ]
Gossec, L. [4 ]
Ostergaard, M. [5 ]
Canete, J. [6 ,7 ]
Gandhi, K. [8 ]
Richards, H. [9 ]
Williams, N. [10 ]
Jugl, S. [9 ]
机构：
[1] Diakonhjemmet Hosp, Oslo, Norway
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Paris 06 Univ, Paris, France
[5] Rigshosp, Copenhagen Ctr Arthrit Res COPECARE, Copenhagen, Denmark
[6] Hosp Clin Barcelona, Barcelona, Spain
[7] IDIBAPS, Barcelona, Spain
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
[10] RTI Hlth Solut, Durham, NC USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.2059
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0421
引用
收藏
页码：823 / 823
页数：1
相关论文
共 50 条
  • [1] Reduction in fatigue in patients with active ankylosing spondylitis: results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Conaghan, P.
    Deodhar, A.
    Gossec, L.
    Ostergaard, M.
    Canete, J.
    Gandhi, K.
    Richards, H.
    Williams, N.
    Jugl, S.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 35 - 36
  • [2] Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies
    Wei, James C. -C.
    Baeten, Dominique
    Sieper, Joachim
    Deodhar, Atul
    Bhosekar, Vaishali
    Martin, Ruvie
    Porter, Brian
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (05) : 589 - 596
  • [3] Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials
    Kvien, Tore K.
    Conaghan, Philip G.
    Gossec, Laure
    Strand, Vibeke
    Ostergaard, Mikkel
    Poddubnyy, Denis
    Williams, Nicole
    Porter, Brian
    Shete, Abhijit
    Gilloteau, Isabelle
    Deodhar, Atul
    [J]. ARTHRITIS CARE & RESEARCH, 2022, 74 (05) : 759 - 767
  • [4] ASAS, BASDAI AND ASDAS REMISSION IN SECUKINUMAB TREATED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A POOLED ANALYSIS OF TWO PHASE 3 STUDIES
    Baraliakos, X.
    Van den Bosch, F.
    Machado, P.
    Gensler, L.
    Bintu, S.
    Porter, B.
    Gaillez, C.
    Deodhar, A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 743 - 743
  • [5] Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
    Baraliakos, Xenofon
    Van den Bosch, Filip
    Machado, Pedro M.
    Gensler, Lianne S.
    Marzo-Ortega, Helena
    Sherif, Bintu
    Quebe-Fehling, Erhard
    Porter, Brian
    Gaillez, Corine
    Deodhar, Atul
    [J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 273 - 288
  • [6] Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
    Xenofon Baraliakos
    Filip Van den Bosch
    Pedro M. Machado
    Lianne S. Gensler
    Helena Marzo-Ortega
    Bintu Sherif
    Erhard Quebe-Fehling
    Brian Porter
    Corine Gaillez
    Atul Deodhar
    [J]. Rheumatology and Therapy, 2021, 8 : 273 - 288
  • [7] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S9 - S9
  • [8] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 355 - 356
  • [9] Reduction in fatigue in patients with active psoriatic arthritis is sustained over 2 years: long-term results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Gossec, L.
    Conaghan, P.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 33 - 33
  • [10] REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS ARE SUSTAINED OVER 2 YEARS: LONG-TERM RESULTS OF TWO PHASE 3 STUDIES WITH SECUKINUMAB
    Gossec, L.
    Kvien, T. K.
    Conaghan, P. G.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 351 - 351
12345